Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …

Next-generation sequencing technologies have enabled a dramatic expansion of clinical
genetic testing both for inherited conditions and diseases such as cancer. Accurate variant …

Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …

We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN
Renal 101 trial (n= 886; NCT02684006), which demonstrated significantly prolonged …

PD-1 blockade has transformed the management of advanced clear cell renal cell
carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely …

Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …

Cancer genome-sequencing studies have revealed a remarkably high prevalence of
mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes …

Molecular alterations in cancer can cause phenotypic changes in tumor cells and their
microenvironment. Routine histopathology tissue slides, which are ubiquitously available …

Cancer is driven by genetic change, and the advent of massively parallel sequencing has
enabled systematic documentation of this variation at the whole-genome scale,–. Here we …

Mutational inactivation of VHL is the earliest genetic event in the majority of clear cell renal
cell carcinomas (ccRCC), leading to accumulation of the HIF-1α and HIF-2α transcription …